Cambridge Investment Research Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-3,510
| Closed | -$247K | – | 3478 |
|
|
2024
Q3 | $247K | Buy |
3,510
+440
| +14% | +$31K | ﹤0.01% | 2980 |
|
|
2024
Q2 | $253K | Buy |
3,070
+524
| +21% | +$43.2K | ﹤0.01% | 2838 |
|
|
2024
Q1 | $222K | Sell |
2,546
-305
| -11% | -$26.6K | ﹤0.01% | 2942 |
|
|
2023
Q4 | $275K | Buy |
2,851
+42
| +1% | +$4.05K | ﹤0.01% | 2656 |
|
|
2023
Q3 | $249K | Sell |
2,809
-1,253
| -31% | -$111K | ﹤0.01% | 2645 |
|
|
2023
Q2 | $352K | Sell |
4,062
-1,027
| -20% | -$89K | ﹤0.01% | 2414 |
|
|
2023
Q1 | $495K | Sell |
5,089
-1,049
| -17% | -$102K | ﹤0.01% | 2080 |
|
|
2022
Q4 | $635K | Buy |
6,138
+460
| +8% | +$47.6K | ﹤0.01% | 1840 |
|
|
2022
Q3 | $481K | Sell |
5,678
-2,302
| -29% | -$195K | ﹤0.01% | 1963 |
|
|
2022
Q2 | $661K | Sell |
7,980
-454
| -5% | -$37.6K | ﹤0.01% | 1746 |
|
|
2022
Q1 | $650K | Sell |
8,434
-3,191
| -27% | -$246K | ﹤0.01% | 1902 |
|
|
2021
Q4 | $1.03M | Sell |
11,625
-9,855
| -46% | -$871K | ﹤0.01% | 1562 |
|
|
2021
Q3 | $1.66M | Buy |
21,480
+3,314
| +18% | +$256K | 0.01% | 1208 |
|
|
2021
Q2 | $1.52M | Buy |
18,166
+8,568
| +89% | +$715K | 0.01% | 1262 |
|
|
2021
Q1 | $725K | Buy |
9,598
+4,154
| +76% | +$314K | ﹤0.01% | 1645 |
|
|
2020
Q4 | $477K | Buy |
5,444
+1,287
| +31% | +$113K | ﹤0.01% | 1798 |
|
|
2020
Q3 | $316K | Sell |
4,157
-74
| -2% | -$5.63K | ﹤0.01% | 1899 |
|
|
2020
Q2 | $522K | Buy |
+4,231
| New | +$522K | ﹤0.01% | 1524 |
|
|
2018
Q1 | – | Sell |
-2,509
| Closed | -$224K | – | 2157 |
|
|
2017
Q4 | $224K | Sell |
2,509
-28
| -1% | -$2.5K | ﹤0.01% | 1845 |
|
|
2017
Q3 | $236K | Buy |
2,537
+192
| +8% | +$17.9K | ﹤0.01% | 1711 |
|
|
2017
Q2 | $213K | Buy |
+2,345
| New | +$213K | ﹤0.01% | 1714 |
|